Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin L Maughan

Showing results (71-80 of 111) with videos related to

Pageof 12
Sort By:
JCO Precision Oncology|May 23, 2024
Differential Tumor Gene Expression Profiling of Patients With Prostate Adenocarcinoma on the Basis of BMIVinay Mathew Thomas, Beverly Chigarira, Georges Gebrael, et al.
The Oncologist|December 22, 2018
Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized TrialBenjamin L Maughan, Sumanta K Pal, David Gill, et al.
The Oncologist|June 22, 2021
Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning PlatformEdwin Lin, Andrew W Hahn, Roberto H Nussenzveig, et al.
The Prostate|July 11, 2020
Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significanceHarsimar Kaur, Iryna Samarska, Jiayun Lu, et al.
Kidney Cancer (Clifton, Va.)|September 12, 2024
Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based CombinationsArshit Narang, Georges Gebrael, Yeonjung Jo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2020
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)Rana R McKay, Bradley A McGregor, Wanling Xie, et al.
Urology Practice|October 30, 2023
Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway InhibitorsGeorges Gebrael, Nicolas Sayegh, Nishita Tripathi, et al.
Plos One|January 26, 2019
Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinomaDavid D Stenehjem, Andrew W Hahn, David M Gill, et al.
Urology Practice|October 31, 2023
Reply by AuthorsGeorges Gebrael, Nicolas Sayegh, Nishita Tripathi, et al.
The Lancet. Oncology|September 16, 2024
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 studyOthon Iliopoulos, Ane B Iversen, Vivek Narayan, et al.
Pageof 12

Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
JCO Precision Oncology|May 23, 2024
Differential Tumor Gene Expression Profiling of Patients With Prostate Adenocarcinoma on the Basis of BMIVinay Mathew Thomas, Beverly Chigarira, Georges Gebrael, et al.
The Oncologist|December 22, 2018
Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized TrialBenjamin L Maughan, Sumanta K Pal, David Gill, et al.
The Oncologist|June 22, 2021
Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning PlatformEdwin Lin, Andrew W Hahn, Roberto H Nussenzveig, et al.
The Prostate|July 11, 2020
Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significanceHarsimar Kaur, Iryna Samarska, Jiayun Lu, et al.
Kidney Cancer (Clifton, Va.)|September 12, 2024
Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based CombinationsArshit Narang, Georges Gebrael, Yeonjung Jo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2020
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)Rana R McKay, Bradley A McGregor, Wanling Xie, et al.
Urology Practice|October 30, 2023
Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway InhibitorsGeorges Gebrael, Nicolas Sayegh, Nishita Tripathi, et al.
Plos One|January 26, 2019
Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinomaDavid D Stenehjem, Andrew W Hahn, David M Gill, et al.
Urology Practice|October 31, 2023
Reply by AuthorsGeorges Gebrael, Nicolas Sayegh, Nishita Tripathi, et al.
The Lancet. Oncology|September 16, 2024
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 studyOthon Iliopoulos, Ane B Iversen, Vivek Narayan, et al.
Pageof 12